

KEYTRUDA® 25 mg/mL concentrate for solution for infusion.

Explanatory note on update to Risk Minimisation Materials

The patient Brochure has been retired. The Patient Card was updated to include diabetic ketoacidosis (and associated symptoms), change immune-related adverse reactions to immune-mediated adverse reactions and to include relevant components from the Patient Information Brochure.

The updated patient card has been mailed to relevant prescribers.

October 2023 (ONCO-Patient card.v14.0)